Current approaches to the adoptive immunotherapy of cancer. View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1988

AUTHORS

J C Yang , S A Rosenberg

ABSTRACT

Interleukin 2 has provided the means of generating activated lymphocytes from the tumor-bearing host which show in vitro anti-tumor activity. These cells can be derived either from a ubiquitous null cell precursor population, exhibiting promiscuous lysis of nearly all tumors after culture in IL2 (ie. the LAK cell) or from a T cell precursor population infiltrating tumors and showing some relative specificity for lysis of the autologous tumor following activation (ie. TIL). When utilized in murine cellular adoptive immunotherapy models, both LAK cells and TIL are able to display marked anti-tumor effects against established micrometastatic tumor. LAK cells have been subsequently employed in adoptive immunotherapy against metastatic human tumors and in a limited number of cases have been able to mediate the regression of advanced cancers of differing histologies. The role of adoptive immunotherapy as standard therapy of human tumors will depend on refinement of the methodology and progress toward increased efficacy and reduced toxicity. TIL may possess theoretical advantages in these areas and efforts are currently proceeding to evaluate these new anti-tumor reagents in the the treatment of patients with cancer. More... »

PAGES

459-67

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-4899-5037-6_50

DOI

http://dx.doi.org/10.1007/978-1-4899-5037-6_50

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1079649344

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/3265581


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytotoxicity, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunization, Passive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interleukin-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Killer Cells, Natural", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Activation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Melanoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Experimental", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "National Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Surgery Branch, National Cancer Institute Bethesda, Md."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yang", 
        "givenName": "J C", 
        "type": "Person"
      }, 
      {
        "familyName": "Rosenberg", 
        "givenName": "S A", 
        "type": "Person"
      }
    ], 
    "datePublished": "1988", 
    "datePublishedReg": "1988-01-01", 
    "description": "Interleukin 2 has provided the means of generating activated lymphocytes from the tumor-bearing host which show in vitro anti-tumor activity. These cells can be derived either from a ubiquitous null cell precursor population, exhibiting promiscuous lysis of nearly all tumors after culture in IL2 (ie. the LAK cell) or from a T cell precursor population infiltrating tumors and showing some relative specificity for lysis of the autologous tumor following activation (ie. TIL). When utilized in murine cellular adoptive immunotherapy models, both LAK cells and TIL are able to display marked anti-tumor effects against established micrometastatic tumor. LAK cells have been subsequently employed in adoptive immunotherapy against metastatic human tumors and in a limited number of cases have been able to mediate the regression of advanced cancers of differing histologies. The role of adoptive immunotherapy as standard therapy of human tumors will depend on refinement of the methodology and progress toward increased efficacy and reduced toxicity. TIL may possess theoretical advantages in these areas and efforts are currently proceeding to evaluate these new anti-tumor reagents in the the treatment of patients with cancer.", 
    "editor": [
      {
        "familyName": "Prodi", 
        "givenName": "Giorgio", 
        "type": "Person"
      }, 
      {
        "familyName": "Liotta", 
        "givenName": "Lance A.", 
        "type": "Person"
      }, 
      {
        "familyName": "Lollini", 
        "givenName": "Pier-Luigi", 
        "type": "Person"
      }, 
      {
        "familyName": "Garbisa", 
        "givenName": "Spiridione", 
        "type": "Person"
      }, 
      {
        "familyName": "Gorini", 
        "givenName": "Sergio", 
        "type": "Person"
      }, 
      {
        "familyName": "Hellmann", 
        "givenName": "Kurt", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-4899-5037-6_50", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-4899-5039-0", 
        "978-1-4899-5037-6"
      ], 
      "name": "Cancer Metastasis", 
      "type": "Book"
    }, 
    "name": "Current approaches to the adoptive immunotherapy of cancer.", 
    "pagination": "459-67", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-4899-5037-6_50"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1079649344"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "3265581"
        ]
      }
    ], 
    "publisher": {
      "location": "Boston, MA", 
      "name": "Springer US", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-4899-5037-6_50", 
      "https://app.dimensions.ai/details/publication/pub.1079649344"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2019-04-15T20:56", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8690_00000182.jsonl", 
    "type": "Chapter", 
    "url": "http://link.springer.com/10.1007/978-1-4899-5037-6_50"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-4899-5037-6_50'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-4899-5037-6_50'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-4899-5037-6_50'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-4899-5037-6_50'


 

This table displays all metadata directly associated to this object as RDF triples.

146 TRIPLES      22 PREDICATES      40 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-4899-5037-6_50 schema:about N0cded5246eaf40109f05fc02734df785
2 N2e72e49e76a64c6596cedf6b799b5357
3 N40ffa7676bbd490e983c28db122c60f3
4 N71f2b63cf0d74d3885bf883e2a00360f
5 N7a0b397ec19347e6baf1069c5ec3578f
6 N9f1185c12a3c47a989658551f2c1d0bb
7 Na4e55c064c1d4526960f593c2f11b28f
8 Na51eb12d18114971b2c8d924bb7c6e71
9 Nbbee78f11e9b461f8e72f80e02e6c27a
10 Nc2a7ccb494ed45909ca78d9bf7b1eb50
11 Nc58e0e59d78d457d90b38e6f62d160e3
12 Nf1c9a6347e5543ef8ec1076f2107c8fa
13 Nfaf0454225054385bd60d467dfc8478e
14 anzsrc-for:11
15 anzsrc-for:1107
16 schema:author N8f0d515b9e194b55851e2e7ec5fa9981
17 schema:datePublished 1988
18 schema:datePublishedReg 1988-01-01
19 schema:description Interleukin 2 has provided the means of generating activated lymphocytes from the tumor-bearing host which show in vitro anti-tumor activity. These cells can be derived either from a ubiquitous null cell precursor population, exhibiting promiscuous lysis of nearly all tumors after culture in IL2 (ie. the LAK cell) or from a T cell precursor population infiltrating tumors and showing some relative specificity for lysis of the autologous tumor following activation (ie. TIL). When utilized in murine cellular adoptive immunotherapy models, both LAK cells and TIL are able to display marked anti-tumor effects against established micrometastatic tumor. LAK cells have been subsequently employed in adoptive immunotherapy against metastatic human tumors and in a limited number of cases have been able to mediate the regression of advanced cancers of differing histologies. The role of adoptive immunotherapy as standard therapy of human tumors will depend on refinement of the methodology and progress toward increased efficacy and reduced toxicity. TIL may possess theoretical advantages in these areas and efforts are currently proceeding to evaluate these new anti-tumor reagents in the the treatment of patients with cancer.
20 schema:editor N4c247ce1be6f463eaad6c9a8c24c50d6
21 schema:genre chapter
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N6dec1322840845eba097d2ce7b8dcbd9
25 schema:name Current approaches to the adoptive immunotherapy of cancer.
26 schema:pagination 459-67
27 schema:productId N307437b333344dae9ad7cb02979ddb0f
28 N7f87642ad9ca4aa4ace61109dd3d8a13
29 Nbadee876804146acbab984cf6c481e3a
30 schema:publisher N9b9611200b544829aded2e4e0138e2c4
31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079649344
32 https://doi.org/10.1007/978-1-4899-5037-6_50
33 schema:sdDatePublished 2019-04-15T20:56
34 schema:sdLicense https://scigraph.springernature.com/explorer/license/
35 schema:sdPublisher N8602510a836340fe877db26399f4b96c
36 schema:url http://link.springer.com/10.1007/978-1-4899-5037-6_50
37 sgo:license sg:explorer/license/
38 sgo:sdDataset chapters
39 rdf:type schema:Chapter
40 N0cded5246eaf40109f05fc02734df785 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
41 schema:name Neoplasm Metastasis
42 rdf:type schema:DefinedTerm
43 N10f8b558a5024b17955e57e5746f63de schema:familyName Rosenberg
44 schema:givenName S A
45 rdf:type schema:Person
46 N2a33146903034a3ea71f782e8288ddde schema:familyName Hellmann
47 schema:givenName Kurt
48 rdf:type schema:Person
49 N2e72e49e76a64c6596cedf6b799b5357 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
50 schema:name Humans
51 rdf:type schema:DefinedTerm
52 N307437b333344dae9ad7cb02979ddb0f schema:name dimensions_id
53 schema:value pub.1079649344
54 rdf:type schema:PropertyValue
55 N3ea3c24993494c7f8b2589d10805387f rdf:first Naeced72dadd34c1bbe7f37fa5677c564
56 rdf:rest Nb0193681e53b4cd586394dcc3b9729bf
57 N40ffa7676bbd490e983c28db122c60f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Melanoma
59 rdf:type schema:DefinedTerm
60 N4c247ce1be6f463eaad6c9a8c24c50d6 rdf:first N8c446e4964b648ea9362a1cf00c81f2d
61 rdf:rest N3ea3c24993494c7f8b2589d10805387f
62 N51e630fc4b6848efa76047f48f13130d schema:affiliation https://www.grid.ac/institutes/grid.48336.3a
63 schema:familyName Yang
64 schema:givenName J C
65 rdf:type schema:Person
66 N6dec1322840845eba097d2ce7b8dcbd9 schema:isbn 978-1-4899-5037-6
67 978-1-4899-5039-0
68 schema:name Cancer Metastasis
69 rdf:type schema:Book
70 N71f2b63cf0d74d3885bf883e2a00360f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Lung Neoplasms
72 rdf:type schema:DefinedTerm
73 N7a0b397ec19347e6baf1069c5ec3578f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Liver Neoplasms
75 rdf:type schema:DefinedTerm
76 N7f87642ad9ca4aa4ace61109dd3d8a13 schema:name doi
77 schema:value 10.1007/978-1-4899-5037-6_50
78 rdf:type schema:PropertyValue
79 N7fc752a7ac8f43b4a42c3ac97ddd1987 rdf:first N2a33146903034a3ea71f782e8288ddde
80 rdf:rest rdf:nil
81 N8602510a836340fe877db26399f4b96c schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 N88a4500ed2ac42408d7693016f610899 schema:familyName Lollini
84 schema:givenName Pier-Luigi
85 rdf:type schema:Person
86 N8c446e4964b648ea9362a1cf00c81f2d schema:familyName Prodi
87 schema:givenName Giorgio
88 rdf:type schema:Person
89 N8f0d515b9e194b55851e2e7ec5fa9981 rdf:first N51e630fc4b6848efa76047f48f13130d
90 rdf:rest Nd36da5696ff6497d8c5c9c8ae958c34a
91 N9b9611200b544829aded2e4e0138e2c4 schema:location Boston, MA
92 schema:name Springer US
93 rdf:type schema:Organisation
94 N9f1185c12a3c47a989658551f2c1d0bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Mice
96 rdf:type schema:DefinedTerm
97 Na4e55c064c1d4526960f593c2f11b28f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Animals
99 rdf:type schema:DefinedTerm
100 Na51eb12d18114971b2c8d924bb7c6e71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Lymphocyte Activation
102 rdf:type schema:DefinedTerm
103 Naeced72dadd34c1bbe7f37fa5677c564 schema:familyName Liotta
104 schema:givenName Lance A.
105 rdf:type schema:Person
106 Nb0193681e53b4cd586394dcc3b9729bf rdf:first N88a4500ed2ac42408d7693016f610899
107 rdf:rest Nd1d03b277bdd44a8afbf304f19a6a898
108 Nbadee876804146acbab984cf6c481e3a schema:name pubmed_id
109 schema:value 3265581
110 rdf:type schema:PropertyValue
111 Nbbee78f11e9b461f8e72f80e02e6c27a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Immunization, Passive
113 rdf:type schema:DefinedTerm
114 Nc2a7ccb494ed45909ca78d9bf7b1eb50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Neoplasms, Experimental
116 rdf:type schema:DefinedTerm
117 Nc58e0e59d78d457d90b38e6f62d160e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Interleukin-2
119 rdf:type schema:DefinedTerm
120 Nc6f4abb5c57c497fafc11e48ab995fd3 schema:familyName Garbisa
121 schema:givenName Spiridione
122 rdf:type schema:Person
123 Nd1d03b277bdd44a8afbf304f19a6a898 rdf:first Nc6f4abb5c57c497fafc11e48ab995fd3
124 rdf:rest Nd5b67951a0a04872b0281a77fcd17c87
125 Nd36da5696ff6497d8c5c9c8ae958c34a rdf:first N10f8b558a5024b17955e57e5746f63de
126 rdf:rest rdf:nil
127 Nd5b67951a0a04872b0281a77fcd17c87 rdf:first Nee88a98f7bf746159740afbd00aadf87
128 rdf:rest N7fc752a7ac8f43b4a42c3ac97ddd1987
129 Nee88a98f7bf746159740afbd00aadf87 schema:familyName Gorini
130 schema:givenName Sergio
131 rdf:type schema:Person
132 Nf1c9a6347e5543ef8ec1076f2107c8fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Killer Cells, Natural
134 rdf:type schema:DefinedTerm
135 Nfaf0454225054385bd60d467dfc8478e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Cytotoxicity, Immunologic
137 rdf:type schema:DefinedTerm
138 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
139 schema:name Medical and Health Sciences
140 rdf:type schema:DefinedTerm
141 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
142 schema:name Immunology
143 rdf:type schema:DefinedTerm
144 https://www.grid.ac/institutes/grid.48336.3a schema:alternateName National Cancer Institute
145 schema:name Surgery Branch, National Cancer Institute Bethesda, Md.
146 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...